Sugi Predict

Sugi Predict / Compounds / SCHEMBL1153293

SCHEMBL1153293

SCHEMBL1153293

C=CC(O)C12OC[C@H](C(C)CCCC(C)C)[C@@]1(C)CCC1=C2CCC2C(C)(C)[C@@H](O)CC[C@@]12C

nearest known ligand 0.51

Predicted protein targets (top 11)

geneUniProtsupporting neighboursconfidence
▸ CRYAB P02511 4/20 0.51
▸ USP2 O75604 2/20 0.51
▸ ALDH1A1 P00352 2/20 0.51
▸ CYP3A4 P08684 2/20 0.51
▸ MAPT P10636 2/20 0.51
▸ ALOX15 P16050 2/20 0.51
▸ LMNA P02545 1/20 0.51
▸ CRYAA P02489 1/20 0.50
▸ PTGES O14684 2/20 0.42
▸ HMGCR P04035 2/20 0.39
▸ ACHE P22303 1/20 0.38

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL9643671 0.84 CRYAB (0.58) CRYABUSP2ALDH1A1CYP3A4MAPT
SCHEMBL9781548 0.84 CRYAB (0.58) CRYABUSP2ALDH1A1CYP3A4MAPT
SCHEMBL9769633 0.78 CRYAB (0.59) CRYABUSP2ALDH1A1CYP3A4MAPT
SCHEMBL13499192 0.77 CRYAB (0.80) CRYABUSP2ALDH1A1CYP3A4MAPT
SCHEMBL7527661 0.77 CRYAB (0.80) CRYABUSP2ALDH1A1CYP3A4MAPT
SCHEMBL568417 0.77 CRYAB (0.80) CRYABUSP2ALDH1A1CYP3A4MAPT
SCHEMBL6130528 0.77 CRYAB (0.80) CRYABUSP2ALDH1A1CYP3A4MAPT
SCHEMBL288306 0.77 CRYAB (0.80) CRYABUSP2ALDH1A1CYP3A4MAPT
SCHEMBL288307 0.77 CRYAB (0.80) CRYABUSP2ALDH1A1CYP3A4MAPT
SCHEMBL19198688 0.77 CRYAB (0.80) CRYABUSP2ALDH1A1CYP3A4MAPT

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 16 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20250302885-A1 RHODOSPIRILLUM RUBRUM CELLS THAT LOWER PLASMA CHOLESTEROL WHILE LEAVING OTHER SERUM PROTEIN LEVELS UNAFFECTED Curador (BE) 2025-10-02 — — US disclosed
EP-4525833-A2 VETERINARY PHARMACEUTICAL FORMULATIONS Increvet, Inc. (US) 2025-03-26 — — EP disclosed
WO-2023225492-A2 VETERINARY PHARMACEUTICAL FORMULATIONS INCREVET, INC. (US) 2023-11-23 — — WO disclosed
US-20230372374-A1 VETERINARY PHARMACEUTICAL FORMULATIONS INCREVET, INC. 2023-11-23 — — US disclosed
WO-2023220930-A1 VETERINARY PHARMACEUTICAL FORMULATIONS CROSS-REFERENCES TO RELATED APPLICATIONS INCREVET, INC. (US) 2023-11-23 — — WO disclosed
US-20220331373-A1 RHODOSPIRILLUM RUBRUM CELLS THAT LOWER PLASMA CHOLESTEROL WHILE LEAVING OTHER SERUM PROTEIN LEVELS UNAFFECTED EZCOL B.V. (NL) 2022-10-20 — — US disclosed
CN-115135331-A Rhodospirillum rubrum cells for lowering plasma cholesterol while leaving other serum protein levels unaffected 埃兹科尔公司 2022-09-30 — — CN disclosed
EP-3989991-A1 RHODOSPIRILLUM RUBRUM CELLS THAT LOWER PLASMA CHOLESTEROL WHILE LEAVING OTHER SERUM PROTEIN LEVELS UNAFFECTED ezCol B.V. (NL) 2022-05-04 — — EP disclosed
US-20130289024-A1 COMPOSITIONS AND METHODS FOR TREATMENT OF FILOVIRUS-MEDIATED DISEASES U.S. ARMY MEDICAL RESEARCH AND MATERIEL COMMAND 2013-10-31 — — US disclosed
US-8475804-B2 Compositions and methods for treatment of filovirus-mediated diseases U.S. ARMY MEDICAL RESEARCH AND MATERIAL COMMAND (US) 2013-07-02 — — US disclosed
US-20110028564-A1 COMPOSITIONS AND METHODS FOR TREATMENT OF FILOVIRUS-MEDIATED DISEASES ZALICUS INC. 2011-02-03 — — US disclosed
US-20100092479-A1 Compositions and methods for treatment of viral diseases COMBINATORX (SINGAPORE) PTE. LTD. (SG) 2010-04-15 — — US disclosed
WO-2010021681-A2 COMPOSITIONS AND METHODS FOR TREATMENT OF VIRAL DISEASES COMBINATORX (SINGAPORE) PTE. LTD. (SG) 2010-02-25 — — WO disclosed
EP-1406660-B1 COMBINATION OF AN ALDOSTERONE RECEPTOR ANTAGONIST AND AN HMG COA REDUCTASE INHIBITOR PHARMACIA CORP (US) 2007-06-06 — — EP disclosed
US-20060003975-A1 Combination of an aldosterone receptor antagonist and an HMG CoA reductase inhibitor PHARMACIA CORPORATION 2006-01-05 — — US disclosed
CN-1537019-A Medical combination of aldosterone receptor antagonist and HMG CoA reductase inhibitor �ź㴫 2004-10-13 — — CN disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20110028564-A1 COMPOSITIONS AND METHODS FOR TREATMENT OF FILOVIRUS-MEDIATED DISEASES FLNA, FLNB, PIGS CRYAB 393/4885USP2 3496/4885ALDH1A1 3453/4885
US-20230372374-A1 VETERINARY PHARMACEUTICAL FORMULATIONS SLC5A2, SLC5A1, SLC2A8 CRYAB 4136/4885USP2 2630/4885ALDH1A1 1551/4885
US-20100092479-A1 Compositions and methods for treatment of viral diseases HAVCR2, RNASE1, EIF2AK2 CRYAB 541/4885USP2 4067/4885ALDH1A1 1588/4885
US-20060003975-A1 Combination of an aldosterone receptor antagonist and an HMG CoA reductase inhibitor HMGCR, NR3C2, LDLR CRYAB 3381/4885USP2 3439/4885ALDH1A1 799/4885
US-20130289024-A1 COMPOSITIONS AND METHODS FOR TREATMENT OF FILOVIRUS-MEDIATED DISEASES FLNA, FLNB, PIGS CRYAB 393/4885USP2 3496/4885ALDH1A1 3453/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.